Diagnosis and treatment of acute and chronic hepatitis C - Procedure in difficult situations;Diagnostik und therapie der akuten und chronischen hepatitis C - Vorgehen in problemsituationen

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 8, 2004, Pages 720-723

  Schmiegel, W H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; INTERFERON; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR;

ACUTE HEPATITIS; ALCOHOL ABUSE; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG CONTRAINDICATION; HEMODIALYSIS; HEMOGLOBINOPATHY; HEPATITIS C; HUMAN; KIDNEY FAILURE; LIVER TRANSPLANTATION; MONOTHERAPY; MUSCLE HYPERTONIA; NEURODERMATITIS; PSORIASIS; REVIEW; SARCOIDOSIS; THYROID DISEASE;

ACUTE DISEASE; AUTOIMMUNE DISEASES; CONSENSUS; DIABETES COMPLICATIONS; FEMALE; GERMANY; HEMOGLOBINOPATHIES; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; ORGAN TRANSPLANTATION; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4444318896     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813445     Document Type: Review

References (38)

1. Hadziyannis SJ, Vassilopoulos D. Complex management issues: management of HCV in the atypical patient. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 277-291 (III)
2. Pol S, Vallet-Pichard A, Fontaine H et al. HCV infection and hemodialysis. Semin Nephrol 2002; 22: 331-339 (IV)
3. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18: 107-116 (IV)
4. Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-451 (IIa)
5. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-966 (Ib)
6. Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000; 95: 1101-1104 (IV)
7. Dobmeier M, Frick E, Frank S et al. Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000; 33: 72-74 (IV)
8. Toth CM, Pascual M, Chung RT et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal tranplantation. Transplantation 1998; 66: 1254-1258 (1V)
9. Durlik M, Gaciong Z, Rancewicz Z et al. Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha. Transplant Proc 1995; 27: 958-959 (III)
10. Rostaing L, Izopet J, Baron E et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431 (IV)
11. Magnone M, Holley JL, Shapiro R et al. Interferon-alpha induced acute renal allograft rejection. Transplantation 1995; 59: 1068-1070 (IV)
12. Dalgard O, Bjoro K, Helium K et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251: 400-406 (Ib)
13. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995; 22: 364-369 (III)
14. Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 2000; 25: 351-352 (IV)
15. Georgetson MJ, Yarze JC, Lalos AT et al. Exazerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88: 1756-1758 (IV)
16. Berger L, Descamps V, Marck Y et al. Alpha interferon-induced eczema in atopic patients infected by hepatitis C virus: 4 case reports. Ann Dermatol Venereol 2000; 127: 51-55 (IV)
17. Tahan V, Ozseker F, Guneylioglu D et al. Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature. Dig Dis Sci 2003; 48: 169-173 (IV)
18. Pohl J, Stremmel W, Kallinowski B. Pulmonal sarcoidosis: A rare side effect of interferon-alpha treatment for chronic hepatitis C infection. Z Gastroenterol 2000; 38: 951-955 (IV)
19. Krehmeier H, Egberts EH. Sarcoidosis after interferon-alpha treatment in hepatitis C. Dtsch Med Wochenschr 2001; 126: 460 (IV)
20. Nemesanszky E, Pusztay M, Csepregi A. Effects of interferon treatment on the glucose metabolism of patients with chronic hepatitis C. Eur J Intern Med 2000; 11: 151-155 (III)
21. Konrad T, Vicini P, Zeuzem S et al. Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes 1999; 107: 343-349 (IIb)
22. Li CK, Chan PK, Ling SC et al. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002; 117 (3): 755-758 (III)
23. Telfer PT, Garson JA, Whitby K et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalasaemic patients. Br J Haematol 1997; 98: 850-855 (III)
24. Swaim MW, Agarwal S, Rosse WF. Successful treatment of hepatitis C in sickle-cell disease. Ann Intern Med 2000; 133: 750-751 (IV)
25. Ono K, Sata M, Murashima S et al. Biological responses to administered interferon in alcoholics. Alcohol Clin Exp Res 1996; 20: 1560-1563 (III)
26. Ohnishi K, Matsuo S, Matsutani K et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374-1379 (IIa)
27. National Institutes of Health Consensus Development Conference Panel statement. Management of hepatitis C. Hepatology 1997; 26 (Suppl.1): 2S-10S (III)
28. EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999; 30: 956-961 (III)
29. Sherman M. Management of viral hepatitis: clinical and public health perspectives - a consensus statement. Can J Gastroenterol 1997; 11: 407-416 (III)
30. Ho SB, Nguyen H, Tetrick LL et al. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96: 157-164 (III)
31. Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135-140 (IIa)
32. Davis GL, Rodrigue JR. Treatment of chronich hepatitis C in active Drug users. N Engl J Med 2001; 345: 23 (IV)
33. Edlin BR, Seal KH, Lorvick J et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-214 (1V)
34. Kochar DM, Penner JD, Knudsen TB. Embryotoxic, teratogenic and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 1980; 52: 99-112 (IIa)
35. Perm VH, Wilhite C, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978; 17: 93-101 (IIa)
36. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19: 67-75 (Ia)
37. Hegenbarthz K, Maurer U, Kroisel PM et al. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. Am J Gastroenterol 2001; 96: 2286-2287 (letter) (IV)
38. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36: 106-113 (III)